Coherus Oncology (CHRS) Projected to Post Quarterly Earnings on Monday

Coherus Oncology (NASDAQ:CHRS) is expected to announce its Q1 2026 results after the market closes on Monday, May 11th. Analysts expect Coherus Oncology to post earnings of ($0.2633) per share and revenue of $14.3410 million for the quarter. Parties can check the company’s upcoming Q1 2026 earning summary page for the latest details on the call scheduled for Monday, May 11, 2026 at 5:00 PM ET.

Coherus Oncology (NASDAQ:CHRS) last issued its earnings results on Monday, March 9th. The biotechnology company reported ($0.34) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.31) by ($0.03). Coherus Oncology had a net margin of 398.42% and a negative return on equity of 860.29%. The company had revenue of $12.75 million during the quarter, compared to analyst estimates of $14.09 million. On average, analysts expect Coherus Oncology to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Coherus Oncology Stock Performance

NASDAQ:CHRS traded up $0.01 during trading hours on Monday, reaching $1.81. 98,133 shares of the stock were exchanged, compared to its average volume of 1,896,499. Coherus Oncology has a 52 week low of $0.71 and a 52 week high of $2.62. The stock has a market capitalization of $279.75 million, a P/E ratio of 1.24 and a beta of 1.01. The company has a quick ratio of 1.45, a current ratio of 1.47 and a debt-to-equity ratio of 0.61. The firm has a 50 day simple moving average of $1.73 and a 200-day simple moving average of $1.63.

Hedge Funds Weigh In On Coherus Oncology

Several hedge funds and other institutional investors have recently modified their holdings of CHRS. Quarry LP bought a new position in shares of Coherus Oncology during the third quarter valued at $26,000. Blair William & Co. IL acquired a new stake in shares of Coherus Oncology in the 4th quarter valued at $27,000. BNP Paribas Financial Markets increased its position in Coherus Oncology by 108.2% in the third quarter. BNP Paribas Financial Markets now owns 26,620 shares of the biotechnology company’s stock worth $44,000 after purchasing an additional 13,832 shares during the period. Two Sigma Investments LP acquired a new position in Coherus Oncology during the 3rd quarter valued at about $59,000. Finally, Focus Partners Wealth acquired a new stake in shares of Coherus Oncology during the 3rd quarter worth approximately $70,000. Institutional investors own 72.82% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have commented on the stock. Weiss Ratings upgraded shares of Coherus Oncology from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Wednesday, April 22nd. Wall Street Zen upgraded Coherus Oncology from a “sell” rating to a “hold” rating in a report on Saturday, March 14th. Finally, Oppenheimer assumed coverage on shares of Coherus Oncology in a research note on Thursday, January 22nd. They issued an “outperform” rating and a $10.00 price objective for the company. Two investment analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $7.00.

Coherus Oncology Company Profile

Coherus Oncology, Inc is a commercial-stage biopharmaceutical company focused on the development, manufacturing and commercialization of biologic therapies for oncology support and immuno-oncology. Founded in 2010 and headquartered in Redwood City, California, Coherus specializes in biosimilar versions of established oncology agents as well as novel immunotherapy candidates.

The company’s lead marketed products include Udenyca (pegfilgrastim-cbqv) and Fulphila (pegfilgrastim-jmdb), biosimilars to Amgen’s Neulasta, which are designed to reduce the incidence of infection in patients undergoing myelosuppressive chemotherapy.